Insider Buying: DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Purchases 128,426 Shares of Stock

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) major shareholder Jan Stahlberg acquired 128,426 shares of the stock in a transaction dated Thursday, November 20th. The stock was bought at an average price of $7.41 per share, for a total transaction of $951,636.66. Following the purchase, the insider owned 8,503,518 shares of the company’s stock, valued at $63,011,068.38. The trade was a 1.53% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Jan Stahlberg also recently made the following trade(s):

• On Tuesday, November 25th, Jan Stahlberg bought 73,099 shares of DiaMedica Therapeutics stock. The shares were bought at an average price of $8.57 per share, with a total value of $626,458.43.
• On Monday, November 24th, Jan Stahlberg purchased 40,253 shares of DiaMedica Therapeutics stock. The stock was bought at an average price of $7.89 per share, for a total transaction of $317,596.17.
• On Friday, November 21st, Jan Stahlberg acquired 208,872 shares of DiaMedica Therapeutics stock. The shares were bought at an average cost of $7.41 per share, with a total value of $1,547,741.52.
• On Wednesday, November 19th, Jan Stahlberg bought 240,352 shares of DiaMedica Therapeutics stock. The stock was bought at an average price of $7.21 per share, with a total value of $1,732,937.92.
• On Tuesday, November 18th, Jan Stahlberg bought 182,882 shares of DiaMedica Therapeutics stock. The shares were purchased at an average cost of $6.75 per share, for a total transaction of $1,234,453.50.
• On Monday, November 17th, Jan Stahlberg purchased 187,393 shares of DiaMedica Therapeutics stock. The stock was purchased at an average cost of $6.52 per share, with a total value of $1,221,802.36.

DiaMedica Therapeutics Stock Down 0.2%

Shares of DMAC stock traded down $0.02 during mid-day trading on Monday, reaching $8.76. The stock had a trading volume of 374,509 shares, compared to its average volume of 251,874. DiaMedica Therapeutics, Inc. has a one year low of $3.19 and a one year high of $9.23. The firm has a market cap of $456.22 million, a PE ratio of -12.34 and a beta of 1.31. The firm’s 50 day simple moving average is $7.11 and its 200 day simple moving average is $5.70.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Sell-side analysts forecast that DiaMedica Therapeutics, Inc. will post -0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada raised its position in DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after purchasing an additional 154,701 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of DiaMedica Therapeutics by 76.7% in the first quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock valued at $462,000 after buying an additional 52,854 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of DiaMedica Therapeutics by 138.5% in the first quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock valued at $382,000 after buying an additional 58,457 shares during the last quarter. Perigon Wealth Management LLC acquired a new position in DiaMedica Therapeutics during the 2nd quarter worth about $207,000. Finally, World Investment Advisors grew its holdings in DiaMedica Therapeutics by 24.7% during the 2nd quarter. World Investment Advisors now owns 31,975 shares of the company’s stock worth $125,000 after acquiring an additional 6,325 shares during the last quarter. 10.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DMAC. Cantor Fitzgerald began coverage on shares of DiaMedica Therapeutics in a research note on Friday, November 14th. They issued an “overweight” rating for the company. Wall Street Zen lowered shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a research note on Friday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, October 8th. Finally, Cowen started coverage on DiaMedica Therapeutics in a report on Thursday, October 30th. They issued a “buy” rating for the company. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $12.33.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.